Exploring the Effect of Colonic J-pouch in Anorectal Preservation Surgery for Ultra-low Rectal Cancer.
NCT06601985
Anastomotic Leak, Behavior
Shanghai, Jingan, China
View Trial DetailsNCT Number: NCT07573371
The goal of this observational study is to learn why some patients develop low anterior resection syndrome (LARS) after colorectal cancer treatment. The study also aims to identify different subtypes of LARS and understand which patients may respond to specific treatments.
The main questions it aims to answer are:
* What physiological and imaging changes are associated with LARS? * How do patients with LARS differ from patients without LARS after colorectal cancer surgery? * Are there measurable differences between LARS, patients treated with organ-preserving chemoradiotherapy, and patients with fecal incontinence?
Participants will:
* Complete advanced physiological and imaging assessments related to bowel function * Be compared with four control groups:
* patients without LARS after colorectal cancer surgery * patients treated with organ-preserving chemoradiotherapy * patients with fecal incontinence and urge fecal incontinence * Take part in a single study visit where all measurements are performed
Interested in participating?
Request Info18 year and older
All sexes
Observational
Aalborg University Hospital, Aalborg, Denmark
Low anterior resection syndrome (LARS) is a common long-term complication after colorectal cancer surgery. Up to 80% of patients experience symptoms such as urgency, frequent bowel movements, clustering, and fecal incontinence. These symptoms can severely affect quality of life, and the underlying causes are not fully understood. LARS appears to result from several interacting mechanisms, including sensory changes, altered motility, reduced reservoir function, sphincter dysfunction, and effects of chemotherapy or radiotherapy. Because different patients may have different dominant mechanisms, treatment responses vary widely.
This observational study aims to investigate the physiological and imaging characteristics of LARS using advanced assessment methods. The goal is to better understand the mechanisms behind LARS, identify distinct patient subtypes, and support development of more targeted treatment strategies.
The study will include 50 patients with minor or major LARS after rectal cancer surgery. Their results will be compared with four control groups:
All participants will attend a single study visit that includes advanced physiological measurements, Magnetic Resonance Imaging (MRI)-based assessments, and standardized questionnaires. These methods are not part of routine clinical care but are used to explore mechanisms such as motility, sensory function, sphincter activity, and rectal reservoir function.
Patients with LARS will also be followed during their standard stepwise treatment pathway. They will complete questionnaires before and during each treatment step, which may include dietary advice, medication, pelvic floor training (biofeedback), and rectal emptying techniques such as mini-enemas or transanal irrigation. This follow-up will help determine how different physiological patterns relate to treatment response.
The study is conducted in collaboration between Aarhus University Hospital and Aalborg University Hospital, with expert input from The Royal London Hospital (UK) and Motilis SA (Switzerland).
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
General:
Specific inclusion criteria for LARS patients:
Specific inclusion criteria for fecal incontinence patients and urge fecal incontinence patients
Specific inclusion criteria for "watch and wait" patients:
Exclusion criteria
General exclusion criteria
Specific exclusion criterias for LARS patients
Time frame: From baseline visit to the end of each standardized treatments at 4 weeks
The EuroQol 5-Dimension, 5-Level questionnaire assesses generic health-related quality of life across five domains: mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. Each domain has five response levels ranging from "no problems" to "extreme problems."
Score range and direction:
Higher scores indicate better health-related quality of life. Includes a visual analogue scale (0-100) where higher scores indicate better self-rated health.
Time frame: From baseline visit to the end of each standardized treatments at 4 weeks
The Low Anterior Resection Syndrome (LARS) Score is a disease-specific symptom questionnaire assessing bowel dysfunction after low anterior resection. It includes five items covering incontinence, frequency, clustering, urgency, and impact on daily life.
Score range and direction:
Total score ranges from 0 to 42. Higher scores indicate more severe bowel dysfunction.
Severity categories:
0-20: No LARS 21-29: Minor LARS 30-42: Major LARS
Time frame: • Applied at baseline and four weeks into all treatment periods
Description:
The St. Mark's Incontinence Score assesses the severity of fecal incontinence across multiple domains, including incontinence to gas, liquid, and solid stool, urgency, use of pads, and lifestyle impact.
Score range and direction:
Total score ranges from 0 to 24. Higher scores indicate more severe fecal incontinence.
Time frame: From baseline visit to the end of each standardized treatments at 4 weeks
The Colostomy Impact Score is a disease-specific questionnaire evaluating the impact of living with a colostomy on daily functioning, social participation, body image, and emotional well-being.
Score range and direction:
Total score ranges from 0 to 100. Higher scores indicate greater negative impact of the colostomy on quality of life.
Time frame: From baseline visit to the end of each standardized treatments at 4 weeks
The Bristol Stool Form Scale classifies stool consistency into seven categories ranging from hard, lumpy stools to entirely liquid stools. It is used as an indicator of bowel transit and stool form.
Score range and direction:
Scale ranges from Type 1 to Type 7. Lower types (1-2) indicate harder stools and slower transit. Middle types (3-4) indicate normal stool form. Higher types (6-7) indicate loose or watery stools and faster transit.
Time frame: From baseline visit to the end of each standardized treatments at 4 weeks
The Patient Assessment of Constipation Symptoms questionnaire measures symptom severity in constipation across three domains: abdominal symptoms, stool symptoms, and rectal symptoms.
Score range and direction:
Each item is scored 0-4; total score ranges from 0 to 48. Higher scores indicate more severe constipation symptoms.
Time frame: From baseline visit to the end of each standardized treatments at 4 weeks
The Wexner Incontinence Score evaluates the severity of fecal incontinence based on frequency of incontinence to gas, liquid, and solid stool, need for pads, and lifestyle alteration.
Score range and direction:
Total score ranges from 0 to 20. Higher scores indicate more severe fecal incontinence.
Time frame: From baseline visit to the end of each standardized treatments at 4 weeks
The Hospital Anxiety and Depression Scale assesses symptoms of anxiety and depression in medical populations. It consists of two subscales: HADS-Anxiety and HADS-Depression.
Score range and direction:
Each subscale ranges from 0 to 21. Higher scores indicate more severe symptoms of anxiety or depression. Total score (0-42) may be reported but is less commonly used.
Time frame: At baseline
Whole-gut and segmental gastrointestinal transit times are measured using the Motilis 3D-Transit system. The system tracks the movement of an electromagnetic capsule through the gastrointestinal tract, allowing calculation of segmental transit times (stomach, small intestine, colon) and total whole-gut transit time. This measure evaluates gastrointestinal motility patterns at baseline.
Score range and direction:
Transit times are continuous measures reported in minutes or hours.
There is no fixed upper or lower limit, as transit times vary physiologically between individuals.
Longer transit times indicate slower gastrointestinal motility.
Shorter transit times indicate faster gastrointestinal motility.
Time frame: At baseline
Magnetic resonance imaging is used at baseline to quantify total colonic volume and segmental colonic volumes (ascending, transverse, descending, sigmoid/rectum colon). Volumes are derived from semi-automated segmentation of the colon on T2-weighted images. This measure evaluates baseline colonic morphology and storage capacity.
Score range and direction:
Colonic volumes are continuous measures reported in milliliters (mL).
There is no fixed upper or lower limit, as volumes vary physiologically between individuals.
Higher values indicate larger colonic or segmental volume.
Lower values indicate smaller colonic or segmental volume.
Time frame: At baseline
Resting anal pressure will be measured using high-resolution anorectal manometry according to standard manometric protocols. Resting anal pressure reflects basal anal sphincter tone, primarily related to internal anal sphincter function. The outcome will be reported as a continuous physiological measure in millimeters of mercury (mmHg). There are no fixed minimum or maximum values because pressures vary physiologically between individuals. Higher values indicate higher resting anal sphincter tone, while lower values indicate reduced resting sphincter tone.
Time frame: At baseline
Maximal voluntary anal squeeze pressure will be measured using high-resolution anorectal manometry according to standard manometric protocols. Squeeze pressure reflects voluntary external anal sphincter contractile strength. The outcome will be reported as a continuous physiological measure in millimeters of mercury (mmHg). There are no fixed minimum or maximum values because pressures vary physiologically between individuals. Higher values indicate stronger voluntary anal sphincter contraction, while lower values indicate reduced voluntary sphincter contractile function.
Time frame: At baseline
The rear-front pressure gradient will be measured using the Fecobionics device during simulated stool evacuation. The Fecobionics device records axial pressure patterns during defecation. The rear-front pressure gradient reflects the pressure difference between the rear and front sensors of the device during evacuation and provides a measure of propulsive force relative to outlet resistance. The outcome will be reported as a continuous physiological measure in millimeters of mercury (mmHg). There are no fixed minimum or maximum values because values vary physiologically between individuals. Higher values indicate stronger propulsive pressure relative to outlet resistance, whereas lower values may indicate impaired propulsion or increased outlet resistance.
Time frame: At baseline
Compare the physioligal findings in LARS patients with a) no-LARS patients, b) organ-preservation patients and c) patient with fecal incontinence
Time frame: From baseline to after 30 minutes of active neuromodulation
Changes in anorectal function measured by the Fecobionics Device
Time frame: From baseline to after 30 minutes of active neuromodulation
Changes in anorectal function measured by high-resolution anorectal manometry
Time frame: From baseline to after active neuromodulation at Visit 2
Changes in anorectal function measured by the Fecobionics Device
Time frame: From baseline to after active neuromodulation at Visit 2
Changes in anorectal function measured by high-resolution anorectal manometry
Time frame: Baseline visit: immediately before stimulation and during active stimulation
The participant's perceived urgency to defecate during the examination will be assessed using a visual analogue scale. Participants with fecal incontinence will rate their urgency to defecate on a numeric scale from 0 to 10, where 0 indicates no desire to defecate and 10 indicates maximal urgency. The outcome will be reported as the change in VAS urgency score from the pre-stimulation assessment to the stimulation assessment at the baseline visit. Higher scores indicate stronger urgency to defecate.
Time frame: At baseline
Resting-state electroencephalography is recorded with the participant at rest to assess baseline cortical activity patterns. Measures include spectral power across standard frequency bands (theta, alpha, beta).
Score range and direction:
Spectral power values are continuous and do not have fixed upper limits.
Higher or lower values reflect differences in cortical activity depending on frequency band.
Time frame: At baseline
Electroencephalography is recorded during rapid rectal balloon distension to elicit cortical evoked potentials. The primary measure is the amplitude of the evoked response to visceral stimulation.
Score range and direction:
Amplitude is measured in microvolts (µV).
Higher amplitudes indicate stronger cortical responses to visceral stimulation.
Time frame: At baseline
Electroencephalography is recorded during rectal balloon distension to measure the latency of cortical evoked potentials, reflecting the timing of sensory pathway activation.
Score range and direction:
Latency is measured in milliseconds (ms).
Longer latencies indicate slower or delayed cortical processing.
Shorter latencies indicate faster neural conduction.
Time frame: Baseline
The defecation index will be derived from Fecobionics measurements obtained during simulated stool evacuation. The index summarizes expulsion performance and anorectal function based on prespecified Fecobionics-derived variables. The outcome will be reported as a continuous index value. There are no fixed minimum or maximum values. Higher values indicate more efficient expulsion and better defecatory performance, whereas lower values indicate reduced defecatory performance.
Contact information is provided by the study sponsor or research team.
Aalborg University Hospital
Other
Acronym: PATO-LARS
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT06601985
Anastomotic Leak, Behavior
Shanghai, Jingan, China
View Trial DetailsNCT05682157
Behavior, Behavioral Symptoms
Jerusalem, Israel
View Trial DetailsNCT05016583
Behavior, Behavioral Symptoms
Jerusalem, Israel
View Trial DetailsNCT06758830
Chemoradiotherapy, Chemotherapy
Vilnius, Lithuania
View Trial Details